Metabolic changes in the basal ganglia of patients with Huntington's disease: An in situ hybridization study of cytochrome oxidase subunit I mRNA

Journal of Neurochemistry

Volumn 80, Issue 3, 2002, Pages 466-476

  Gourfinkel An, Isabelle ^a   Vila, Miquel ^a,c   Faucheux, Baptiste ^a   Duyckaerts, Charles ^a   Viallet, François ^b   Hauw, Jean Jacques ^a   Brice, Alexis ^a   Agid, Yves ^a   Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CENTRE HOSPITALIER DU PAYS D AIX   (France)

^c Columbia Univ Coll Phys Surgeons ^*  (United States)

Author keywords

Basal ganglia; Cytochrome oxidase; Huntington's disease; In situ hybridization

Indexed keywords

CHLORPROMAZINE; CYAMEMAZINE; CYTOCHROME C OXIDASE; HALOPERIDOL; LEVOMEPROMAZINE; MESSENGER RNA; NEUROLEPTIC AGENT; THIOPROPERAZINE; THIORIDAZINE;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CADAVER; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME SUBUNIT; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IN SITU HYBRIDIZATION; LONG TERM CARE; NERVE DEGENERATION; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; ELECTRON TRANSPORT COMPLEX IV; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HUNTINGTON DISEASE; IN SITU HYBRIDIZATION; MIDDLE AGED; NEURONS; RNA, MESSENGER;

EID: 0036488133     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-3042.2001.00734.x     Document Type: Article

References (60)

1. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Albin R. L., Young A. B., Penney J. B., Handelin B., Balfour R., Anderson K. D., Markel D. S., Tourtelotte W. W. and Reiner A. (1990a) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. N. Eng. J. Med. 322, 1293-1298.
3. Albin R. L., Reiner A., Anderson K. D., Penney J. B. and Young A. B. (1990b) Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27, 357-365.
4. Alexander G. E. and Crutcher M. D. (1990) Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
5. Bamford K. A., Caine E. D., Kido D. K., Plassche W. M. and Shoulson I. (1989) Clinical-pathologic correlation in Huntington's disease: a neuropsychological and computed tomography study. Neurology 39, 796-801.
6. Bruyn G. W. (1973) Clinical variants and differential diagnosis. Neuropathological changes, in Huntington's Chorea. Advances in Neurology (Barbeau A., Chase T. N. and Paulson G. W., eds), pp. 51-56, 399-403. Raven Press, New York.
7. Chesselet M. F., Weiss L., Wuenschell C., Tobin A. J. and Affolter H. U. (1987) Comparative distribution of RNAs for glutamic acid decarboxylase, tyrosine hydroxylase and tachykinins in the basal ganglia: an in situ hybridization study in the rodent brain. J. Comp. Neurol. 262, 125-140.
8. Cudkowicz M. and Kowall N. W. (1990) Degeneration of pyramidal projection neurons in Huntington's disease cortex. Ann. Neurol. 27, 200-204.
9. Dawbarn D., Dequidt M. E. and Emson P. C. (1985) Survival of basal ganglia neuropeptide Y-somatostatin neurons in Huntington's disease. Brain Res. 340, 251-260.
10. De la Monte S. M., Vonsattel J.-P. and Richardson E. P. (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol. 47, 516-525.
11. Delfs J. M., Anegawa N. J. and Chesselet M. F. (1995a) Glutamate decarboxylase messenger RNA in rat pallidum: comparison of the effects of haloperidol, clozapine and combined haloperidolscopolamine treatments. Neuroscience 66, 67-80.
12. Delfs J. M., Ellison G. D., Mercugliano M. and Chesselet M. F. (1995b) Expression of glutamic acid decarboxylase RNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp. Neurol. 133, 175-188.
13. DeLong M. R. (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13, 281-285.
14. Ellison D. W., Beal M. F., Mazurek M. F., Malloy J. R., Bird E. D. and Martin J. B. (1987) Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain 110, 1657-1673.
15. Emson P. C., Arregui A., Clement-Jones V., Sandberg B. E. and Rossor M. (1980) Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease. Brain Res. 199, 147-160.
16. Ferrante R. J., Kowall N. W., Beal M. F., Richardson E. P. Jr., Bird E. D. and Martin J. B. (1986) Topography of enkephalin, substance P, and acetylcholinesterase staining in Huntington's disease striatum. Neurosci. Lett. 71, 283-288.
17. Ferrante R. J., Beal M. F., Kowall N. W., Richardson E. P. Jr and Martin J. B. (1987a) Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 12, 162-166.
18. Ferrante R. J., Kowall N. W., Beal M. F., Martin J. B., Bird E. D. and Richardson E. P. Jr (1987b) Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. J. Neuropathol. Exp. Neurol. 46, 12-27.
19. Fontaine B., Sassoon D., Buckingham M. and Changeux J. P. (1988) Detection of the nicotinic acetylcholine receptor subunit mRNA by in situ hybridization at neuromuscular junction of 15-day-old chick striatal muscles. EMBO J. 7, 603-607.
20. Goldberg Y. P., Andrew S. E., Clarke L. A. and Hayden M. R. (1993) A PCR method for accurate assessment of trinucleotide repeat expansion in Huntington disease. Hum. Mol. Genet. 2, 635-636.
21. Grafe M. R., Forno L. S. and Eng L. F. (1985) Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer diseases. J. Neuropathol. Exp. Neurol. 44, 47-59.
22. Graveland G. A., Williams R. S. and DiFiglia M. A. (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227, 770-773.
23. Graybiel A. M. (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-253.
24. Graybiel A. M. and Ragsdale C. W. (1978) Histochemically distinct compartments in the striatum of human, monkey and cat demonstrated by acetylcholinesterase staining. Proc. Natl Acad. Sci. 75, 5723-5726.
25. Hayden M. R., Soles J. A. and Ward R. H. (1985) Age of onset in siblings of persons with juvenile Huntington's disease. Clin. Genet. 28, 100-105.
26. Hedreen J. C. and Folstein S. E. (1995) Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropath. Exp. Neurol. 54, 105-120.
27. Hedreen J. C., Peyser C. E., Folstein S. E. and Ross C. A. (1991) Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease. Neurosci. Lett. 133, 257-261.
28. Herrero M. T., Levy R., Ruberg M., Luquin M. R., Villares J., Guillen J., Faucheux B., Javoy-Agid F., Guridi J., Agid Y., Obeso J. A. and Hirsch E. C. (1996) Consequence of nigrostriatal denervation and 1-dopa therapy on the expression of glutamic decarboxylase messenger RNA in the pallidum. Neurology 47, 219-224.
29. Hevner R. F. and Wong-Riley M. T. T. (1991) Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analyzed by in situ hybridization: comparison with CO activity and protein. J. Neurosci. 11, 1942-1958.
30. Hirsch E. C., Perier C., Orieux G., François C., Féger J., Yelnik J., Vila M., Levy R., Tolosa E. S., Marin C., Herrero M.-T., Obeso J. A. and Agid Y. (2000) Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 23, S78-S85.
31. Javoy-Agid F., Hirsch E. C., Dumas S., Duyckaerts C., Mallet J. and Agid Y. (1990) Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson disease: an in situ hybridization study. Neuroscience 38, 245-253.
32. Yu J., Kallstrom L., Wiesel F. A. and Johnson A. E. (1999) Neurochemical changes in the entopeduncular nucleus and increased oral behavior in rats treated subchronically with clozapine or haloperidol. Synapse 34, 192-207.
33. Kowall N. W., Ferrante R. J. and Martin J. B. (1987) Patterns of cell loss in Huntington's disease. Trends Neurosci. 10, 24-29.
34. Kuhl D. E., Phelps M. E., Markham C. H., Metter E. J., Riege W. H. and Winter J. (1982) Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan. Ann. Neurol. 12, 425-434.
35. LaManna J. C., Kutina-Nelson K. L., Hritz M. A., Huang Z. and Wong-Riley M. T. (1996) Decreased rat brain cytochrome oxidase activity after prolonged hypoxia. Brain Res. 720, 1-6.
36. Lange H., Thorner G., Hopf A. and Schroder K. F. (1976) Morphometric studies of the neuropathological changes in choreatic diseases. J. Neurol. Sci. 28, 401-425.
37. Lasker A. G., Zee D. S., Hain T. C., Folstein S. E. and Singer H. S. (1988) Saccades in Huntington's disease: slowing and dysmetria. Neurology 38, 427-431.
38. Levy R., Hazrati L.-N., Herrero M.-T., Vila M., Hassani O.-K., Mouroux M., Ruberg M., Asensi H., Agid Y., Féger J., Obeso J. A., Parent A. and Hirsch E. C. (1997) Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience 76, 335-343.
39. McCaughey W. T. E. (1961) The pathologic spectrum of Huntington's chorea. J. Nerv. Ment. Dis. 133, 91-103.
40. Mercugliano M., Saller C. F., Salama A. I., U'Prichard D. C. and Chesselet M. F. (1992) Clozapine and haloperidol have differential effects on glutamic acid decarboxylase mRNA in the pallidal nuclei of the rat. Neuropharmacology 6, 179-187.
41. Monfort J. C., Javoy-Agid F., Hauw J. J., Dubois B. and Agid Y. (1985) Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index. Brain 108, 301-313.
42. Orieux G., François C., Féger J., Yelnik J., Vila M., Ruberg M., Agid Y. and Hirsch E. C. (2000) Metabolic activity of excitatory parafascicular and pedonculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97, 79-88.
43. Oyanagi K., Takeda S., Takahashi H., Ohama E. and Ikuta F. (1989) A quantitative investigation of the substantia nigra in Huntington's disease. Ann. Neurol. 26, 13-19.
44. Parent A. and Cicchetti F. (1998) The current model of basal ganglia organization under scrutiny. Mov. Disord. 13, 199-202.
45. Penney J. B. and Young A. B. (1983) Speculations on the functional anatomy of basal ganglia disorders. Annu. Rev. Neurosci. 6, 73-94.
46. Penney J. B., Young A. B., Shoulson I., Starosta-Rubenstein S., Snodgrass S. R., Sanchez-Ramos J., Ramos-Arroyo M., Gomez F., Penchaszadeh G., Alvir J., Esteves J., DeQuiroz I., Marsol N., Moreno H., Conneally P. M., Bonilla E. and Wexler N. S. (1990) Huntington's disease in Venezuela: eight years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 5, 93-99.
47. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B. and Young A. B. (1988) Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl Acad. Sci. USA 85, 5733-5737.
48. Reynolds G. P. and Pearson S. J. (1987) Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain. Neurosci. Lett. 78, 233-238.
49. Roos R. A. C., Pruyt J. F. M., de Vries J. and Bots G. (1985) Neuronal distribution in the putamen in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 48, 422-425.
50. Sotrel A., Paskevich P. A., Kiely D. K., Bird E. D., Williams R. S. and Myers R. H. (1991) Morphometric analysis of the prefrontal cortex in Huntington's disease. Neurology 41, 1117-1123.
51. Storey E. and Beal M. F. (1993) Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 116, 1201-1222.
52. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome. Cell 72, 971-983.
53. Urquhart N., Perry T. L., Hansen S. and Kennedy J. (1975) GABA content and glutamic acid decarboxylase activity in brain of Huntington's chorea patients and control subjects. J. Neurochem. 24, 1071-1075.
54. Vila M., Levy R., Herrero M.-T., Faucheux B., Obeso J. A., Agid Y. and Hirsch E. C. (1996) Metabolic activity of the basal ganglia in the Parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. Neuroscience 71, 903-912.
55. Vila M., Levy R., Herrero M.-T., Ruberg M., Faucheux B., Obeso J. A., Agid Y. and Hirsch E. C. (1997) Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. J. Neurosci. 17, 765-773.
56. Vila M., Périer C., Féger J., Yelnik J., Faucheux B., Ruberg M., Raisman-Vozari R., Agid Y. and Hirsch E. C. (2000) Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiologic measurements. Europ. J. Neurosci. 12, 337-344.
57. Vonsattel J. P., Myers R. H., Stevens T. J., Ferrante R. J., Bird E. D. and Richardson E. P. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
58. Wakai M., Takahashi A. and Hashizume Y. (1993) A histometrical study on the globus pallidus in Huntington's disease. J. Neurol. Sci. 119, 18-27.
59. Wong-Riley M. T. T. (1989) Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 12, 94-101.
60. Young A. B., Shoulson I., Penney J. B., Starosta-Rubinstein S. and Gomez F. (1986) Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36, 244-249.